Carnitine in Alleviation of Complications Caused by Acute Valproic Acid Toxicity; an Exprimental Study on Mice
Archives of Academic Emergency Medicine,
Vol. 12 No. 1 (2024),
1 January 2024
,
Page e20
https://doi.org/10.22037/aaem.v12i1.2146
Abstract
Introduction: Hyperammonemia and hepatotoxicity are well-known complications of valproic acid (VPA) poisoning. The objective of this study is to evaluate the potential role of carnitine in mitigating the adverse effects of acute VPA toxicity in mice.
Methods: 54 male mice (25-30 g) were randomly assigned to one of three categories, including acute, sub-acute, and chronic poisoning. Each category contained 3 groups, each consisting of 6 mice (Group 1: control, Group 2: VPA treated, and Group 3: VPA + carnitine treated). The animals were sacrificed 24 hours after the initial injection, and their blood, liver, and brain samples were compared between groups of each category regarding liver function biomarkers, oxidative stress markers, ammonia level, and liver histopathologic changes using one-way ANOVA followed by Tukey’s multiple comparison test.
Results: The administration of VPA increased the serum level of aspartate aminotransferase (AST) (p=0.003) and alanine aminotransferase (ALT) (p=0.001), as well as serum, and brain level of ammonia (p=0.0001 for both) in the intervention group. Elevated levels of lipid peroxidation and oxidative stress (p=0.0001 for both) in the liver tissue, decreased liver glutathione (p=0.0001) and ferric ion-reducing antioxidant power (FRAP) (p=0.0001), and histopathologic changes in the form of moderate to severe inflammation were observed. Administration of VPA + carnitine reduced AST (p=0.05) and ALT (p=0.01), increased the FRAP, reduced free oxygen radicals and liver lipid peroxidation (p=0.0001 for all), and decreased tissue damage in the form of moderate inflammation. The administration of carnitine was ineffective in reducing brain or plasma ammonia levels in acute VPA-treated animals (p = 0.0115).
Conclusions: Although the administration of carnitine has been suggested as a protective remedy in cases of VPA toxicity, according to the present study, it did not have an antidotal effect and did not prevent encephalopathy or liver injury in acute VPA toxicity.
- Valproic acid
- Chemical and drug induced liver injury
- Hepatic encephalopathy
- Carnitine
How to Cite
References
Böhles H, Sewell A, Wenzel D. The effect of carnitine supplementation in valproate‐induced hyperammonaemia. Acta Paediatrica. 1996;85(4):446-9.
Marini AM, Zaret BS, Beckner RR. Hepatic and renal contributions to valproic acid‐induced hyperammonemia. Neurology. 1988;38(3):365-.
Verrotti A, Trotta D, Morgese G, Chiarelli F. Valproate-induced hyperammonemic encephalopathy. Metabolic brain disease. 2002;17:367-73.
Okamura N, Ohnishi S, Shimaoka H, Norikura R, Hasegawa H. Involvement of recognition and interaction of carnitine transporter in the decrease of L-carnitine concentration induced by pivalic acid and valproic acid. Pharmaceutical research. 2006;23:1729-35.
Sztajnkrycer MD. Valproic acid toxicity: overview and management. Journal of Toxicology: Clinical Toxicology. 2002;40(6):789-801.
Eyer F, Felgenhauer N, Gempel K, Steimer W, Gerbitz K-D, Zilker T. Acute valproate poisoning: pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. Journal of clinical psychopharmacology. 2005;25(4):376-80.
Camilleri C, Albertson T, Offerman S. Fatal cerebral edema after moderate valproic acid overdose. Annals of emergency medicine. 2005;45(3):337-8.
Berthelot-Moritz F, Chadda K, Chanavaz I, Leroy J, Droy J, Bonmarchand G, et al. Fatal sodium valproate poisoning. Intensive care medicine. 1997;23(5):599.
Knapp AC, Todesco L, Beier K, Terracciano L, Sägesser H, Reichen J, et al. Toxicity of valproic acid in mice with decreased plasma and tissue carnitine stores. Journal of pharmacology and experimental therapeutics. 2008;324(2):568-75.
Sugimoto T, Araki A, Nishida N, Sakane Y, Woo M, Takeuchi T, et al. Hepatotoxicity in rat following administration of valproic acid: effect of L‐carnitine supplementation. Epilepsia. 1987;28(4):373-7.
Gopaul S, Farrell K, Abbott F. Effects of age and polytherapy, risk factors of valproic acid (VPA) hepatotoxicity, on the excretion of thiol conjugates of (E)‐2, 4‐diene VPA in people with epilepsy taking VPA. Epilepsia. 2003;44(3):322-8.
Russell S. Carnitine as an antidote for acute valproate toxicity in children. Current opinion in pediatrics. 2007;19(2):206-10.
Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Annals of Pharmacotherapy. 2010;44(7-8):1287-93.
Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity–what is the evidence? Critical Care. 2005;9:1-10.
Johannessen CU, Johannessen SI. Valproate: past, present, and future. CNS drug reviews. 2003;9(2):199-216.
Watson WA, Litovitz TL, Klein-Schwartz W, Rodgers Jr GC, Youniss J, Reid N, et al. 2003 annual report of the American association of poison control centers toxic exposure surveillance system. The American journal of emergency medicine. 2004;22(5):335-404.
Chang TK, Abbott FS. Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug metabolism reviews. 2006;38(4):627-39.
Khoo S, Leyland M. Cerebral edema following acute sodium valproate overdose. Journal of Toxicology: Clinical Toxicology. 1992;30(2):209-14.
Tennison MB, Miles MV, Pollack GM, Thorn MD, Dupuis RE. Valproate metabolites and hepatotoxicity in an epileptic population. Epilepsia. 1988;29(5):543-7.
Murakami K, Sugimoto T, Woo M, Nishida N, Muro H. Effect of L‐carnitine supplementation on acute valproate intoxication. Epilepsia. 1996;37(7):687-8.
Mohammadi H, Heidari R, Niknezhad SV, Jamshidzadeh A, Farjadian F. In vitro and in vivo Evaluation of Succinic Acid-Substituted Mesoporous Silica for Ammonia Adsorption: Potential Application in the Management of Hepatic Encephalopathy. International Journal of Nanomedicine. 2020;15:10085-98.
Farshad O, Keshavarz P, Heidari R, Farahmandnejad M, Azhdari S, Jamshidzadeh A. The potential neuroprotective role of citicoline in hepatic encephalopathy. Journal of Experimental Pharmacology. 2020;12:517-27.
Ommati MM, Ahmadi HN, Sabouri S, Retana-Marquez S, Abdoli N, Rashno S, et al. Glycine protects the male reproductive system against lead toxicity via alleviating oxidative stress, preventing sperm mitochondrial impairment, improving kinematics of sperm, and blunting the downregulation of enzymes involved in the steroidogenesis. Environmental Toxicology. 2022;37(12):2990-3006.
Farshad O, Ommati MM, Yüzügülen J, Jamshidzadeh A, Mousavi K, Ahmadi Z, et al. Carnosine mitigates biomarkers of oxidative stress, improves mitochondrial function, and alleviates histopathological alterations in the renal tissue of cholestatic rats. Pharmaceutical Sciences. 2020;27(1):32-45.
Heidari R, Jamshidzadeh A, Ghanbarinejad V, Ommati MM, Niknahad H. Taurine supplementation abates cirrhosis-associated locomotor dysfunction. Clinical and Experimental Hepatology. 2018;4(2):72-82.
Jamshidzadeh A, Abdoli N, Niknahad H, Azarpira N, Mardani E, Mousavi S, et al. Taurine alleviates brain tissue markers of oxidative stress in a rat model of hepatic encephalopathy. Trends in Pharmaceutical Sciences. 2017;3(3):181-92.
Shafiekhani M, Ommati MM, Azarpira N, Heidari R, Salarian AA. Glycine supplementation mitigates lead-induced renal injury in mice. Journal of Experimental Pharmacology. 2019;11:15-22.
Ommati MM, Manthari RK, Tikka C, Niu R, Sun Z, Sabouri S, et al. Arsenic-induced autophagic alterations and mitochondrial impairments in HPG-S axis of mature male mice offspring (F1-generation): A persistent toxicity study. Toxicology Letters. 2020;326:83-98.
Ommati MM, Farshad O, Mousavi K, Taghavi R, Farajvajari S, Azarpira N, et al. Agmatine alleviates hepatic and renal injury in a rat model of obstructive jaundice. PharmaNutrition. 2020;13:100212.
Ommati MM, Farshad O, Niknahad H, Mousavi K, Moein M, Azarpira N, et al. Oral administration of thiol-reducing agents mitigates gut barrier disintegrity and bacterial lipopolysaccharide translocation in a rat model of biliary obstruction. Current Research in Pharmacology and Drug Discovery. 2020;1:10-8.
Ommati MM, Farshad O, Mousavi K, Jamshidzadeh A, Azmoon M, Heidari S, et al. Betaine supplementation mitigates intestinal damage and decreases serum bacterial endotoxin in cirrhotic rats. PharmaNutrition. 2020;12:100179.
Mousavi K, Niknahad H, Li H, Jia Z, Manthari RK, Zhao Y, et al. The activation of nuclear factor-E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) signaling blunts cholestasis-induced liver and kidney injury. Toxicology Research. 2021;10(4):911-27.
Ommati MM, Farshad O, Azarpira N, Shafaghat M, Niknahad H, Heidari R. Betaine alleviates cholestasis-associated renal injury by mitigating oxidative stress and enhancing mitochondrial function. Biologia. 2021;76(1):351-65.
Ishikura H, Matsuo N, Matsubara M, Ishihara T, Takeyama N, Tanaka T. Valproic acid overdose and L-carnitine therapy. Journal of analytical toxicology. 1996;20(1):55-8.
Ahangar N, Naderi M, Noroozi A, Ghasemi M, Zamani E, Shaki F. Zinc deficiency and oxidative stress involved in valproic acid induced hepatotoxicity: protection by zinc and selenium supplementation. Biological trace element research. 2017;179:102-9.
Laub MC, Paetzke‐Brunner I, Jaeger G. Serum carnitine during valproic acid therapy. Epilepsia. 1986;27(5):559-62.
Raza M, Al-Bekairi A, Ageel A, Qureshi S. Biochemical basis of sodium valproate hepatotoxicity and renal tubular disorder: time dependence of peroxidative injury. Pharmacological research. 1997;35(2):153-7.
Pourahmad J, Eskandari MR, Kaghazi A, Shaki F, Shahraki J, Fard JK. A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis. Toxicology in Vitro. 2012;26(4):545-51.
Shakoor KA, Khan K. Valproic acid-induced hepatotoxicity and protective role of carnitine. Pakistan Pediatric Journal. 1997;21(3):133-4.
Romero-Falcón A, de la Santa-Belda E, Garcı́a-Contreras R, Varela JM. A case of valproate-associated hepatotoxicity treated with L-carnitine. European Journal of Internal Medicine. 2003;14(5):338-40.
Brown LM, Cupples N, Moore TA. Levocarnitine for valproate-induced hyperammonemia in the psychiatric setting: A case series and literature review. Mental Health Clinician. 2018;8(3):148-54.
Tichelbäcker T, Herath J, Tampe B, Korsten P. Hemodiafiltration Treatment for Severe Valproic Acid Intoxication: Case Report and Updated Systematic Literature Review. Frontiers in Medicine. 2018;5:224.
Temel V, Arikan M, Temel G. High-flux hemodialysis and levocarnitine in the treatment of severe valproic Acid intoxication. Case Reports in Emergency Medicine. 2013;2013.
Dealberto M-JC. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. International clinical psychopharmacology. 2007;22(6):330-7.
Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clinical Toxicology. 2009;47(2):101-11.
Rigamonti A, Lauria G, Grimod G, Bianchi G, Salmaggi A. Valproate induced hyperammonemic encephalopathy successfully treated with levocarnitine. Journal of Clinical Neuroscience. 2014;21(4):690-1.
Baddour E, Tewksbury A, Stauner N. Valproic acid–induced hyperammonemia: Incidence, clinical significance, and treatment management. Mental Health Clinician. 2018;8(2):73-7.
Böhles H, Richter K, Wagner-Thiessen E, Schäfer H. Decreased serum carnitine in valproate induced Reye syndrome. European Journal of Pediatrics. 1982;139:185-6.
Ohtani Y, Matsuda I. Valproate treatment and carnitine deficiency. Neurology. 1984;34(8):1128-.
Zimmerman HJ, Ishak KG. Valproate‐induced hepatic injury: analyses of 23 fatal cases. Hepatology. 1982;2(5):591S-7S.
Krähenbühl S, Mang G, Kupferschmidt H, Meier P, Krause M. Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity. Gut. 1995;37(1):140-3.
Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase γ gene POLG determines the risk of sodium valproate‐induced liver toxicity. Hepatology. 2010;52(5):1791-6.
- Abstract Viewed: 324 times
- pdf Downloaded: 1001 times